An Introduction to Haematological Malignancies
In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”
Haematological Malignancies Content
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):Online ahead of journal publication
**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process**
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Precision medicine in RRMM: Understanding how the data can be applied to practice
Watch a panel of experts discuss the latest advances in the treatment of relapsed and/or refractory multiple myeloma and the potential for precision medicine.
- Describe the current challenges in the treatment of multiple myeloma and considerations for overcoming poor prognosis
- Discuss the efficacy and safety data of novel agents being investigated in patients with RRMM
- Describe approaches to selecting treatment for patients with RRMM and the potential for precision medicine
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.
- Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
- Summarize the adverse events associated with second-generation BTK inhibitors
- Review current management recommendations for people with Waldenström’s macroglobulinaemia
Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma
Oncology & Hematology Review (US). 2020; 16(1):12–4 DOI: https://doi.org/10.17925/OHR.2020.16.1.12
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma.1 Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM,2 MM remains incurable, with a high disease burden.3 Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance.4 An increasing number […]
Current management of relapsed/refractory multiple myeloma and the future integration of BCMA-targeting agents
Watch a panel of internationally renowned multiple myeloma experts discuss the management of relapsed/refractory disease and the future for B-cell maturation antigen (BCMA)-targeted agents
- Discuss how treatment for patients with relapsed/refractory multiple myeloma can be selected based on disease- and patient-related factors
- Describe the rationale for B-cell maturation antigen (BCMA) as a treatment target and current agents in development
- Recall the latest data for BCMA-targeting agents in relapsed/refractory multiple myeloma and consider how they may be incorporated into clinical practice
CAR-T in clinical practice: Navigating the patient journey from referral to long-term follow-up
Get an update on CAR-T therapy in clinical practice with this expert discussion on real-world data, patient referral and the important collaboration between referral and treatment centres.
- Recall the latest real-world evidence for the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL)
- Describe which patients with DLBCL should be referred for assessment for CAR-T therapy and discuss the importance of early referral
- Discuss the roles of referral centres and treatment centres in patient management, in particular long-term follow up of patients
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!